Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics (Nasdaq: VYGR), a gene therapy innovator, has announced its participation in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR), a gene therapy innovator, has announced its participation in two upcoming virtual investor conferences. The company will present at the SVB Leerink 11th Annual Global Healthcare Conference on Feb. 18, 2022, at 9:20 a.m. ET, and participate in a corporate panel at the Cowen 42nd Annual Health Care Conference on Mar. 9, 2022, at 12:50 p.m. ET. Investors can access the sessions on Voyager's website and replays will be available for at least 30 days.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was -4.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced that it will participate in the following virtual investor conferences.
- SVB Leerink 11th Annual Global Healthcare Conference, company presentation, Feb. 18, 2022, 9:20 a.m. ET
- Cowen 42nd Annual Health Care Conference, corporate panel discussion, Mar. 9, 2022, 12:50 p.m. ET
The sessions may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER™ screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Investor Inquiries:
investors@voyagertherapeutics.com
Media Inquiries:
Scott Santiamo
ssantiamo@voyagertherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.